Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience.
OBJECTIVE
To evaluate the efficacy and safety of zonisamide (ZNS) as long-term adjunctive therapy in children with Lennox-Gastaut syndrome (LGS).


METHODS
We evaluated the seizure frequency, cognitive outcomes, and side effects of 62 LGS patients maintained on ZNS for at least 12 months in three tertiary centers.


RESULTS
Of the 62 LGS patients maintained on ZNS, 3 (4.8%) had 100% seizure control; 14 (22.6%) had >75% to <100% reduction in seizure frequency; 15 (24.2%) had >50% to <75% reduction in seizure frequency; 6 (9.7%) had >0% to <50% reduction in seizure frequency, and 24 (38.7%) had no seizure reduction. Seizure outcomes were not related to seizure types or etiologies. Adverse events included somnolence and anorexia, but all were transient and successfully managed by careful follow-up.


CONCLUSIONS
Our results indicate that adjunctive treatment with ZNS is safe and effective in pediatric LGS patients.
You
Su Jeong
SJ
Department of Pediatrics, Epilepsy Center, Inje University College of Medicine, Sanggye Paik Hospital, Seoul, South Korea.
Kang
Hoon-Chul
HC
Kim
Heung Dong
HD
Lee
Hyun Sug
HS
Ko
Tae-Sung
TS
D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007555:Isoxazoles / Q000008:administration & dosage* / Q000009:adverse effects; D007723:Korea; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome; D000078305:Zonisamide
D000927:Anticonvulsants; D007555:Isoxazoles; D000078305:Zonisamide